Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Depreciation and Depletion (2020 - 2023)

Insight Molecular Diagnostics' Depreciation and Depletion history spans 4 years, with the latest figure at $404000.0 for Q3 2023.

  • For Q3 2023, Depreciation and Depletion rose 3.32% year-over-year to $404000.0; the TTM value through Sep 2023 reached $1.8 million, up 32.55%, while the annual FY2022 figure was $1.5 million, 81.04% up from the prior year.
  • Depreciation and Depletion for Q3 2023 was $404000.0 at Insight Molecular Diagnostics, down from $435000.0 in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $466000.0 in Q4 2022 and bottomed at -$216000.0 in Q4 2020.
  • The 4-year median for Depreciation and Depletion is $287000.0 (2022), against an average of $264933.3.
  • The largest YoY upside for Depreciation and Depletion was 221.3% in 2021 against a maximum downside of 36.57% in 2021.
  • A 4-year view of Depreciation and Depletion shows it stood at -$216000.0 in 2020, then skyrocketed by 221.3% to $262000.0 in 2021, then soared by 77.86% to $466000.0 in 2022, then decreased by 13.3% to $404000.0 in 2023.
  • Per Business Quant, the three most recent readings for IMDX's Depreciation and Depletion are $404000.0 (Q3 2023), $435000.0 (Q2 2023), and $450000.0 (Q1 2023).